Impact of theophylline use in Wolff-Parkinson-White syndrome.
Methylxanthine use in the treatment of apnea of prematurity is well documented. This drug is avoided in patients with aberrant pathways of conduction such as Wolff-Parkinson-White syndrome. In theory, methylxanthines enhance precipitation and exacerbation of tachyarrhythmias to which these patients are predisposed. This article reports a case of Wolff-Parkinson-White syndrome in a preterm neonate with severe apneic episodes in which methylxanthines were used. However, no adverse effects on cardiac rate or rhythm were encountered.
Agwunobi
J
J
District of Columbia General Hospital, Washington, DC 20003, USA.
Abedin
M
M
Young
M
M
Beeram
M
M
Sinkford
S
S
D000628:Aminophylline / Q000009:adverse effects / Q000627:therapeutic use*; D001049:Apnea / Q000150:complications / Q000188:drug therapy; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004562:Electrocardiography; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy; D008297:Male; D012127:Respiratory Distress Syndrome, Newborn / Q000150:complications* / Q000188:drug therapy*; D013806:Theophylline / Q000097:blood; D014927:Wolff-Parkinson-White Syndrome / Q000150:complications*
D001993:Bronchodilator Agents; D002316:Cardiotonic Agents; D000628:Aminophylline; D013806:Theophylline